Key Takeaways
- Volume surges but prices mask it: Sales value rose only 2% QoQ, yet volumes grew more than 30% as chemical prices fell significantly across the board. EBITDA jumped more than 50% QoQ, driven by that volume growth and margin improvement.
- Manufacturing pivot to exports lifts margins: Manufacturing margins improved significantly despite only 5% revenue growth, because the company concentrated on export markets that give better realisations and managed inventory better.
- NMA reaches commercial milestone: First commercial batches shipped to key domestic and US customers, with repeat orders expected this quarter, marking a tangible new revenue stream.
- Polyacrylamide solids on track for Q3 FY25: Soft technology is largely developed and equipment technology work is underway; the commercial launch target remains Q3 FY25, opening a product line where Black Rose is the only alternative to China.
- What to watch next quarter: Whether NMA repeat orders materialise and scale, the pace of export recovery in Acrylamide solids, and any formal announcement on the specialty chemicals JV with the Japanese principal.
Volume vs. Value: The Quarter's Divergence
- Price headwinds obscured volume strength: Chemical prices fell significantly across the board, so sales value rose only 2% QoQ even as volumes grew more than 30%.
- Raw material tailwind emerging: Acrylonitrile prices, which had fallen continuously over the last year, stabilised at about $950/ton early in the quarter and firmed to $1,150-1,200/ton by quarter-end, a move that should support better realisations going forward.
- Export mix shift was deliberate, not a loss: Export business fell to about one-third of revenue from 45% in the prior quarter, but the entire decline came from reduced merchant export business; manufacturing export revenue actually increased.
- Key products carried the quarter: Ethanolamine, purified isophthalic acid, and Acrylonitrile were strong, driving both improved revenue and EBITDA.
Daga: "we really don't study the capacity utilization with much significance while we try to, you know, improve our overall sales volumes and profitability. So, that is how we benchmark our performance and not to that extent the capacity utilization, because this additional capacity comes, you know, at a very, very, very low CapEx."
Manufacturing Margin Recovery
- Export focus drove better realisations: Manufacturing margins improved significantly even though revenue grew only 5%, because the company concentrated on export markets and managed inventory better.
- Distribution margins also up 20% QoQ: Stable demand, new customer penetration, and strong principal support on both supply and pricing lifted distribution margins.
- Acrylamide solids export strategy is a pricing play: Black Rose is the only alternative to China for this product, giving it good acceptance on quality and availability, and better price realisation in export markets. Management says it is very competitive with Chinese companies under a fair pricing policy.
- US oil and gas a near-term drag: Export volumes face subdued demand from the US oil and gas sector due to lower demand and geopolitical pressures; recovery is expected from the next financial year.
- Domestic Acrylamide solid pressured by dumping: Continuous dumping from China makes it difficult to sell Acrylamide solid in the domestic market, reinforcing the export focus.
NMA: The New Revenue Stream
- First commercial shipments delivered: Initial commercial batches have been shipped to a key domestic customer and a key US customer, with validation received from the domestic customer.
- Repeat orders expected this quarter: Management expects repeat orders from these large customers during the current quarter, which would significantly improve NMA sales in both the current and coming quarters.
- Revenue contribution not disclosed: Management declined to provide exact revenue figures for NMA when asked.
Product Pipeline & Expansion
- Polyacrylamide solids on track for Q3 FY25: Soft technology is largely developed; the team is now working on equipment technology. Once production starts, the company expects good export volumes, as the solid form overcomes the logistics cost barrier that makes liquid exports uneconomic.
- Polyacrylamide liquid export economics are prohibitive: The product has low concentration and low price, making logistics costs too high to export the liquid form profitably.
- Specialty chemicals JV in advanced discussion: A project with a Japanese principal is in advanced stages, to be set up at the existing Jhagadia plant; management hopes to have something by FY25.
- Toll manufacturing discussions underway: The company is already in discussion with a US and a European company on toll manufacturing projects related to Acrylamide chemistries.
- R&D building and newer products: An R&D building is in the pipeline, hoped to be in place by next year. Work is progressing on polycarboxylate dispersant for the tile industry and newer versions of ceramic binder.
- Space already earmarked: Enough space exists at the existing Jhagadia site for all upcoming projects, including the JV and toll manufacturing.
Daga: "until now China was the only producer for Acrylamide solids and now we are the only alternate to China, so we have good acceptance of our product in terms of quality as well as availability and with that better price realization, we are concentrating on expanding our export business for the Acrylamide solids."
Market Position & Competitive Dynamics
- Morbi strategy is quality-led, not price-led: The Morbi market is competitive with many small manufacturers; Black Rose is not fighting for market share via price competition but is focusing on product quality and service, and says it is continually gaining market share and acceptance.
- Market share undisclosed: Management declined to comment when asked if the company holds more than 50% market share in the Morbi polyacrylamide liquid market.
- No competitor supply issues: Management confirmed there are no current supply issues from any competitors; the market is very competitive.
- Turkish REACH registration near completion: Expected to be finalised by the end of this year, which will support European market reach.
Segment Outlook
- Distribution: Expects stronger sales volumes and good margins, supported by principal backing on supplies and pricing.
- Key products for the current quarter: Resorcinol, isophthalic, and ethanolamines are expected to improve in both volume and revenue. Ethanolamine volumes increased in the current quarter and the outlook is positive with expectations of further volume increases and good profitability.
- Polyacrylamide liquids: Demand expected to be robust with the festive season and increased export of ceramic tiles; higher sales volume with improved margins anticipated due to raw material pricing.
- Geographical mix shift: Management expects the distribution/manufacturing revenue ratio to move closer to 50% in future quarters as manufacturing activity picks up.
- Capacity expansion: A decision to increase capacities will be taken when there is consistent capacity utilisation beyond a certain threshold; management declined to quantify current utilisation, saying it benchmarks on sales volumes and profitability instead.
Daga: "the product is not very highly concentrated, so that is one drawback and it is not a very, you know, high priced item, so the logistics cost would normally make it quite difficult to export the liquid form. However, you know once we start producing the polyacrylamide solid, we would be able to have good export volumes for that product."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Polyacrylamide solids commercial launch | Commercial production to begin | Q3 FY25 |
| NMA repeat orders | Repeat orders from large domestic and US customers expected to significantly improve sales | Current quarter and coming quarters |
| Turkish REACH registration | Registration finalised, supporting European market access | End of calendar year |
| Specialty chemicals JV with Japanese principal | Formal agreement for project at Jhagadia plant | FY25 |
| R&D building | Building in place | Next year |
| Export recovery (merchant) | Subdued US oil and gas export volumes to improve | Next financial year |
| Distribution/manufacturing revenue mix | Ratio to move closer to 50% | Future quarters |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | +2% QoQ; volumes up more than 30% QoQ offset by lower chemical prices |
| Standalone EBITDA growth | 48% |
| EBITDA vs Q2 FY23 | ~2.5x; Q2 FY23 EBITDA was about 5.34% |
| EBITDA vs Q1 FY24 | +50% QoQ |
| EPS (previous quarter) | 1.18 |
| Return on equity and ROCE | +50% YoY |
| Long-term debt | Zero |
| Distribution margins | +20% QoQ |
| Distribution EBITDA vs Q2 FY23 | ~2x |
| Manufacturing revenue | +5%; lower price realisations offset by volume growth |
| Manufacturing volume growth | ~15% |
| Distribution volume growth | ~50% |
| Chemical distribution revenue share | ~2/3rd of total revenue |
| Export revenue share | ~1/3rd; down from 45% in Q1 FY24 due to reduced merchant exports |
| Top 5 products revenue share | 75% of topline |
| Top 5 products profit share | 72% of profit |
| Acrylonitrile price range | $950/ton at quarter start, settling at $1,150–$1,200/ton by quarter end |
| Acrylamide liquid capacity | 32,000 MTPA; 20,000 MT for merchant sales, balance captive |
| Polyacrylamide liquid capacity | 40,000 MTPA |
| N-methylol Acrylamide capacity | 2,000 MT |
| Acrylamide solid capacity | 3,600 MT |
| Polyacrylamide solids commercial launch target | Q3 FY25 |
| Morbi share of India ceramic tile manufacturing | ~80% |